Huntington’s Disease Treatment

Global Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Drug Type (Approved Drugs (Tetrabenazine and Deutetrabenazine) and Offlabel Drugs), By Distribution Channel, By Age, By Regional Outlook and Forecast, 2024 - 2031

Report Id: KBV-23451 Publication Date: July-2024 Number of Pages: 266
USD 407.8 Million
USD 805.1 Million
Historical Data
2020 to 2022

Market Report Description

The Global Huntington's Disease Treatment Market size is expected to reach $805.1 million by 2031, rising at a market growth of 9.0% CAGR during the forecast period.

The Asia-Pacific region's nations are investing in expanding and modernizing its hospitals, clinics, and specialized treatment facilities. Better facilities and access to healthcare enable HD patients to receive sophisticated treatment choices, interdisciplinary care, and early diagnosis. Consequently, the Asia pacific region would acquire nearly 25% of the total market share by 2031. Genetic diversity within the Asia Pacific region provides unique opportunities for studying Huntington’s Disease genetics, disease variants, and population-specific factors influencing disease progression.

Huntington's Disease Treatment Market Size - Global Opportunities and Trends Analysis Report 2020-2031

Huntington’s disease is caused by a mutation in the HTT gene, which produces an abnormal form of the huntingtin protein. Moreover, RNA interference (RNAi) and antisense oligonucleotides (ASOs) are biotechnological approaches that can reduce the expression of the mutant HTT gene. Moreover, RNA interference (RNAi) and antisense oligonucleotides (ASOs) are biotechnological approaches that can reduce the expression of the mutant HTT gene. Additionally, Healthcare expenditure encompasses funding allocated to biomedical research, including neurodegenerative diseases like Huntington’s disease. Furthermore, investments in healthcare infrastructure, such as specialized clinics, research centers, and laboratory facilities, are essential for advancing HD research and treatment. Therefore, rising healthcare expenditures and investments are propelling the market’s growth.

However, A poisonous mutant huntingtin protein (mHTT) results from an HTT gene mutation that causes HD. This genetic mutation leads to neuronal dysfunction and eventual neurodegeneration. Moreover, the clinical manifestations of HD vary widely among individuals, both in terms of symptom onset and progression. Thus, complex disease pathophysiology is hampering the growth of the market.

The pandemic led to the suspension or delay of many clinical trials for Huntington’s Disease due to lockdowns, travel restrictions, and the reallocation of healthcare resources to address COVID-19. In addition, the global supply chain disruptions caused by the pandemic affected the availability of medications and medical supplies for HD patients. Thus, the COVID-19 pandemic had a negative impact on the market.

Driving and Restraining Factors
Huntington’s Disease Treatment
  • Advancements in genetic research and biotechnology
  • Rising healthcare expenditure and investments
  • Increasing prevalence of Huntington’s disease (HD)
  • Complex disease pathophysiology
  • Limited treatment options
  • Growing government initiatives
  • Rise of telemedicine and digital health
  • High development costs
  • Ethical and genetic counseling issues

Drug Type Outlook

Based on drug type, the Huntington's Disease Treatment Market is divided into approved drugs and offlabel drugs. In 2023, the offlable drugs segment acquired 15.3% revenue share in the Huntington's Disease Treatment Market. Off-label drugs may offer potential benefits in managing specific symptoms of Huntington’s Disease, such as psychiatric symptoms (e.g., depression, anxiety), irritability, and cognitive impairment. Healthcare providers may explore off-label options to alleviate these challenging symptoms that significantly impact patient quality of life.

Huntington's Disease Treatment Market Share and Industry Analysis Report 2023

Distribution Channel Outlook

On the basis of distribution channel, the Huntington's Disease Treatment Market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. In 2023, the drug stores & retail pharmacies segment attained 32.7% revenue share in the Huntington's Disease Treatment Market. Retail pharmacies stock a variety of medications used to manage symptoms associated with Huntington’s Disease, including medications for chorea (involuntary movements), psychiatric symptoms (e.g., depression, anxiety), and cognitive impairments.

Age Outlook

By age, the Huntington's Disease Treatment Market is bifurcated into below 50 years and above 50 years. The above 50 segment held 43.3% revenue share in the Huntington's Disease Treatment Market in 2023. Huntington’s Disease can present with subtle or atypical symptoms in older adults, leading to delays in diagnosis. As awareness and diagnostic capabilities improve, more individuals above 50 years old may receive a diagnosis of HD, prompting the initiation of treatment and management strategies to address symptoms and optimize quality of life.

Free Valuable Insights: Global Huntington's Disease Treatment Market size to reach USD 805.1 Million by 2031

Regional Outlook

Region-wise, the Huntington's Disease Treatment Market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed 42% revenue share in the Huntington's Disease Treatment Market in 2023. North America has a relatively higher Huntington’s Disease prevalence than other regions. The disease is more commonly diagnosed among populations of European descent, which are prominent in North America. Also, the region is a global leader in biomedical research and pharmaceutical innovation.

Huntington's Disease Treatment Market Report Coverage
Report Attribute Details
Market size value in 2023 USD 407.8 Million
Market size forecast in 2031 USD 805.1 Million
Base Year 2023
Historical Period 2020 to 2022
Forecast Period 2024 to 2031
Revenue Growth Rate CAGR of 9.0% from 2024 to 2031
Number of Pages 266
Number of Tables 410
Report coverage Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Porter’s 5 Forces Analysis, Company Profiling, Companies Strategic Developments, SWOT Analysis, Winning Imperatives
Segments covered Drug Type, Distribution Channel, Age, Region
Country scope
  • North America (US, Canada, Mexico, and Rest of North America)
  • Europe (Germany, UK, France, Russia, Spain, Italy, and Rest of Europe)
  • Asia Pacific (China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific)
  • LAMEA (Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA)
Companies Included Bausch Health Companies, Inc., Teva Pharmaceutical Industries Ltd., Camber Pharmaceuticals, Inc. (Hetero Labs Limited), Hikma, Pharmaceuticals PLC, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Neurocrine Biosciences Inc., Pfizer, Inc. and F. Hoffmann-La Roche Ltd.
Need a report that reflects how COVID-19 has impacted this market and its growth? Download Free Sample Now

List of Key Companies Profiled

  • Bausch Health Companies, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
  • Hikma Pharmaceuticals PLC
  • Takeda Pharmaceutical Company Limited
  • Sun Pharmaceutical Industries Ltd.
  • Dr.Reddy’s Laboratories Ltd.
  • Neurocrine Biosciences Inc.
  • Pfizer, Inc.
  • F.Hoffmann-La Roche Ltd.

Huntington’s Disease Treatment Report Segmentation

By Drug Type

  • Approved Drugs
    • Tetrabenazine
    • Deutetrabenazine
  • Offlabel Drugs

By Distribution Channel

  • Hospital Pharmacies
  • Drug Store & Retail Pharmacies
  • Online Pharmacies

By Age

  • Below 50 years
  • Above 50 years

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA


Call: +1(646) 600-5072


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo